ArticleCommunications medicine2026
Host factors, inflammatory markers, and clinical outcomes of Naegleria fowleri meningoencephalitis.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary amoebic meningoencephalitis (PAM) caused by Naegleria fowleri carries historical case fatality rates (CFR) exceeding 97%. The 2025 Kerala outbreak, the largest documented globally, provided an unprecedented opportunity to identify host factors and inflammatory correlates influencing survival under standardised management.
methodsWe conducted a prospective observational study of 200 laboratory-confirmed PAM cases across six districts of Kerala, India (January-November 2025). All patients received protocolised amphotericin B ± miltefosine. Demographic, clinical, and laboratory data were collected, including inflammatory biomarkers (IL-6, TNF-α, IL-1β, neutrophil-to-lymphocyte ratio), pathogen burden (qPCR), and treatment timing. Multivariable logistic regression identified mortality predictors; bootstrap resampling and E-value sensitivity analyses assessed robustness.
resultsHere we show that among 200 patients (median age 41 years; 50% male), 134 with resolved outcomes yield a CFR of 45·5% (95% CI 37·3-54·5%; 61 deaths, 73 recoveries). Diabetes mellitus is the only statistically significant predictor of mortality in the adjusted model (adjusted OR 2·59; 95% CI 1·01-6·66; p = 0·048), though the proximity of the lower confidence bound to unity warrants cautious interpretation. This association remains consistent across sensitivity analyses (bootstrap 95% CI 1·06-8·74; E-value 4·62). Asthma demonstrates a protective association in univariable analysis (OR 0·37; p = 0·021), though this finding remains hypothesis-generating. Early treatment (≤2 days) shows a trend toward improved survival (p = 0·084). Inflammatory biomarkers show no association with outcome, though CSF pathogen burden correlates significantly with admission neurological severity.
conclusionsUnder standardised treatment, diabetes mellitus emerges as a key host determinant of PAM mortality. The dissociation between inflammatory markers and outcomes suggests neurological fate may be determined early in infection, with immediate clinical implications as climate change expands the geographic range of N. fowleri.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.